# Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

**Authors:** Ping Gong, Yifan Wang, Pengfei Zhang, Zhaogang Yang, Weiye Deng, Zhihong Sun, Mingming Yang, Xuefeng Li, Gongcheng Ma, Guanjun Deng, Shiyan Dong, Lintao Cai, Wen Jiang

PMC · DOI: 10.3390/cancers13010077 · Cancers · 2020-12-30

## TL;DR

This paper reviews immunocyte membrane-coated nanoparticles as a promising approach to improve cancer immunotherapy by leveraging natural cell membrane properties for better drug delivery.

## Contribution

The paper provides a comprehensive review of immunocyte membrane-coated nanoparticles, highlighting their advantages and challenges in cancer immunotherapy.

## Key findings

- Immunocyte membrane-coated nanoparticles offer biocompatibility and protection from immune recognition.
- These nanoparticles face challenges in large-scale preparation and application.
- They have potential to enhance targeted drug delivery and tumor immunotherapy effectiveness.

## Abstract

Cancer immunotherapy is a breakthrough in cancer treatment. Unfortunately, despite the encouraging results in clinical treatment, cancer immunotherapy such as CAR-T, PD-1 still faces lots of challenges. Therefore, it is necessary to develop new methods to improve the effectiveness and safety of tumor immunotherapy. In recent years, cell membrane-coated nanomaterial is one of the most promising drug delivery systems and is receiving a great deal of attention due to its naturally biocompatible characteristics. This review summarizes the latest research progress, the advantages, the disadvantages, and the application of immunocyte membrane-coated nanoparticles in cancer immunotherapy.

Despite the advances in surface bioconjugation of synthetic nanoparticles for targeted drug delivery, simple biological functionalization is still insufficient to replicate complex intercellular interactions naturally. Therefore, these foreign nanoparticles are inevitably exposed to the immune system, which results in phagocytosis by the reticuloendothelial system and thus, loss of their biological significance. Immunocyte membranes play a key role in intercellular interactions, and can protect foreign nanomaterials as a natural barrier. Therefore, biomimetic nanotechnology based on cell membranes has developed rapidly in recent years. This paper summarizes the development of immunocyte membrane-coated nanoparticles in the immunotherapy of tumors. We will introduce several immunocyte membrane-coated nanocarriers and review the challenges to their large-scale preparation and application.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** Itga4 (integrin alpha 4) [NCBI Gene 16401] {aka CD49D, Itga4B}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, IRF3 (interferon regulatory factor 3) [NCBI Gene 3661] {aka IIAE7}, Inhca (inhibitor of carbonic anhydrase) [NCBI Gene 71775] {aka 1300017J02Rik, Ica, mICA}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, Icam1 (intercellular adhesion molecule 1) [NCBI Gene 15894] {aka CD54, Icam-1, Ly-47, MALA-2}, CD2 (CD2 molecule) [NCBI Gene 914] {aka LFA-2, SRBC, T11}, Serpinb1-ps1 (serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene) [NCBI Gene 282665] {aka EID, ovalbumin}, CALHM6 (calcium homeostasis modulator family member 6) [NCBI Gene 441168] {aka C6orf187, FAM26F, INAM, dJ93H18.5}, NECTIN2 (nectin cell adhesion molecule 2) [NCBI Gene 5819] {aka CD112, HVEB, PRR2, PVRL2, PVRR2}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, Cnr1 (cannabinoid receptor 1) [NCBI Gene 12801] {aka CB-R, CB1, CB1A, CB1B, CB1R}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, KMT2E (lysine methyltransferase 2E (inactive)) [NCBI Gene 55904] {aka HDCMC04P, MLL5, NKp44L, ODLURO, SETD5B}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, NR1I3 (nuclear receptor subfamily 1 group I member 3) [NCBI Gene 9970] {aka CAR, CAR1, MB67}, PCNA (proliferating cell nuclear antigen) [NCBI Gene 5111] {aka ATLD2}, Cd226 (CD226 antigen) [NCBI Gene 225825] {aka DNAM-1, DNAM1, Pta1, TLiSA1}, Tnfsf11 (tumor necrosis factor (ligand) superfamily, member 11) [NCBI Gene 21943] {aka Ly109l, ODF, OPGL, RANKL, Trance}, Pvr (poliovirus receptor) [NCBI Gene 52118] {aka 3830421F03Rik, CD155, D7Ertd458e, HVED, PVS, Taa1}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, Rab10 (RAB10, member RAS oncogene family) [NCBI Gene 19325], NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, ITGAL (integrin subunit alpha L) [NCBI Gene 3683] {aka CD11A, EV6, HNA-5, LFA-1, LFA1A}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, FCER1G (Fc epsilon receptor Ig) [NCBI Gene 2207] {aka FCRG}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CCR2 (C-C motif chemokine receptor 2) [NCBI Gene 729230] {aka CC-CKR-2, CCR-2, CCR2A, CCR2B, CD192, CKR2}, Klrk1 (killer cell lectin-like receptor subfamily K, member 1) [NCBI Gene 27007] {aka D6H12S2489E, NKG2-D, Nkg2d}, SIRPA (signal regulatory protein alpha) [NCBI Gene 140885] {aka BIT, CD172A, MFR, MYD-1, MYD1, P84}, CD80 (CD80 molecule) [NCBI Gene 941] {aka B7, B7-1, B7.1, BB1, CD28LG, CD28LG1}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, NCR2 (natural cytotoxicity triggering receptor 2) [NCBI Gene 9436] {aka CD336, LY95, NK-p44, NKP44, dJ149M18.1}, NCR1 (natural cytotoxicity triggering receptor 1) [NCBI Gene 9437] {aka CD335, LY94, NK-p46, NKP46}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, CD58 (CD58 molecule) [NCBI Gene 965] {aka LFA-3, LFA3, ag3}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, Vcam1 (vascular cell adhesion molecule 1) [NCBI Gene 22329] {aka CD106, Vcam-1}, CD247 (CD247 molecule) [NCBI Gene 919] {aka CD3-ZETA, CD3H, CD3Q, CD3Z, CD3ZETA, IMD25}, Ncr1 (natural cytotoxicity triggering receptor 1) [NCBI Gene 17086] {aka Cd335, Ly94, NKp46}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, Pcna (proliferating cell nuclear antigen) [NCBI Gene 18538], Irgm1 (immunity-related GTPase family M member 1) [NCBI Gene 15944] {aka Ifggd3, Ifi1, Iigp3, Iipg3, Irgm}, CD48 (CD48 molecule) [NCBI Gene 962] {aka BCM1, BLAST, BLAST1, MEM-102, SLAMF2, hCD48}, Nectin2 (nectin cell adhesion molecule 2) [NCBI Gene 19294] {aka Cd112, MPH, Pvr, Pvrl2, Pvs, nectin-2}, Mill2 (MHC I like leukocyte 2) [NCBI Gene 243864] {aka Micb}, CD47 (CD47 molecule) [NCBI Gene 961] {aka IAP, MER6, OA3}, PMEL (premelanosome protein) [NCBI Gene 6490] {aka D12S53E, HMB-45, HMB45, ME20, ME20-M, ME20M}, CARTPT (CART prepropeptide) [NCBI Gene 9607] {aka CART}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, Trav6-3 (T cell receptor alpha variable 6-3) [NCBI Gene 328483] {aka Gm13948, Gm193, Gm4, TCR}
- **Diseases:** brain tumors (MESH:D001932), inflammation (MESH:D007249), tumorigenesis (MESH:D063646), lung metastases (MESH:D009362), Glioblastoma (MESH:D005909), central nervous system disorders (MESH:D002493), macrophage (MESH:D055501), Tumor (MESH:D009369), breast cancer (MESH:D001943), metastatic (MESH:D000092182), glioma (MESH:D005910), malignant melanoma (MESH:D008545), skull tumor (MESH:D012888), ICD (MESH:D003643), HCC (MESH:D006528), toxicity (MESH:D064420), acute monocytic leukemia (MESH:D007948), DC-cancer (MESH:D018295)
- **Chemicals:** Saikosaponin D (MESH:C025759), carbon (MESH:D002244), Durvalumab (MESH:C000613593), azide (MESH:D001386), bismuth selenide (MESH:C000613026), Quercetin (MESH:D011794), lipopolysaccharide (MESH:D008070), chitosan (MESH:D048271), carbohydrates (MESH:D002241), Alemtuzumab (MESH:D000074323), TCPP (MESH:C018395), silica (MESH:D012822), paraformaldehyde (MESH:C003043), polymers (MESH:D011108), ROS (MESH:D017382), PLGA (MESH:D000077182), lipid (MESH:D008055), Trametinib (MESH:C560077), Fe3O4 (MESH:C000499), PMA (MESH:D013755), Ac4ManN-BCN (-), PEGs (MESH:D011092), DOX (MESH:D004317), paclitaxel (MESH:D017239)
- **Species:** Lyssavirus rabies (species) [taxon 11292], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** U-87 MG — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0022), 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC7794746/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC7794746/full.md

## References

128 references — full list in the complete paper: https://tomesphere.com/paper/PMC7794746/full.md

---
Source: https://tomesphere.com/paper/PMC7794746